아페레시스 시장 : 성분별, 제품별, 기술별, 시술별, 용도별, 최종사용자별, 지역별(2025-2033년)

The global apheresis market size reached USD 3.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.6 Billion by 2033, exhibiting a growth rate (CAGR) of 6.26% during 2025-2033.

Apheresis is a procedure of separating donated blood components, such as red blood cells (RBCs), white blood cells (WBCs), platelets, and plasma, to treat various diseases. It assists in treating sickle cell disease wherein red blood cells (RBCs) are shaped abnormally and cannot carry oxygen through the body. It is also employed to remove abnormal white blood cells (WBCs) that thicken the blood and interfere with organ function. In addition, as it aids in treating blood cancers and blood disorders, such as myasthenia gravis and thrombotic thrombocytopenic purpura (TTP), apheresis is widely used in blood collection centers, hospitals, and ambulatory centers across the globe.

Apheresis Market Trends:

The growing demand for apheresis to treat various diseases, such as autoimmune hemolytic anemia, acute disseminated encephalomyelitis, and cardiac neonatal lupus, represents one of the key factors driving the market. Besides this, there is a rise in the utilization of apheresis to collect plasma for treating burnt and trauma patients across the globe. This, along with the burgeoning healthcare industry, is contributing to the growth of the market. Moreover, increasing investments by key market players in research and development (R&D) activities to introduce an enhanced blood purification device that treats severe forms of arteriosclerosis obliterans is positively influencing the market. In addition, the rising demand for source plasma to treat primary immunodeficiency and hemophilia is offering lucrative growth opportunities to industry investors. Apart from this, the growing employment of apheresis as a therapy for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure, is offering a positive market outlook. Additionally, the increasing awareness among the masses about the benefits of apheresis is bolstering the growth of the market.

Key Market Segmentation:

Breakup by Component:

• Plasma (Plasmapheresis)
• Platelets (Plateletpheresis)
• Leukocytes (Leukapheresis or Leukopheresis)
• Lymphocytes (Lymphopheresis or Lymphapheresis)
• RBC's (Erythropheresis)

Breakup by Product:

• Devices
• Disposables and Reagents
• Software

Breakup by Technology:

• Centrifugation
• Membrane Separation
• Selective Adsorption

Breakup by Procedure:

• Donor/Automated Apheresis
• Therapeutic Apheresis

Breakup by Application:

• Renal Disorders
• Hematological Disorders
• Neurological Disorders
• Autoimmune Disorders
• Others

Breakup by End User:

• Blood Centers
• Hospitals
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Asahi Kasei Medical Co. Ltd. (Asahi Kasei Corporation), B. Braun SE, Charles River Laboratories International Inc., Fresenius Medical Care AG & Co. KGaA, Haemonetics Corporation, Haier Biomedical, Kaneka Corporation, Medica S.p.a., Miltenyi Biotec, Nikkiso Co. Ltd., Sb-Kawasumi Laboratories Inc. (Sumitomo Bakelite Company Limited) and Terumo Bct Inc. (Terumo Corporation).

Key Questions Answered in This Report

• 1.What was the size of the global apheresis market in 2024?
• 2.What is the expected growth rate of the global apheresis market during 2025-2033?
• 3.What are the key factors driving the global apheresis market?
• 4.What has been the impact of COVID-19 on the global apheresis market?
• 5.What is the breakup of the global apheresis market based on the component?
• 6.What is the breakup of the global apheresis market based on the product?
• 7.What is the breakup of the global apheresis market based on the technology?
• 8.What is the breakup of the global apheresis market based on procedure?
• 9.What is the breakup of the global apheresis market based on the application?
• 10.What is the breakup of the global apheresis market based on the end user?
• 11.What are the key regions in the global apheresis market?
• 12.Who are the key players/companies in the global apheresis market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Apheresis Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Component

• 6.1 Plasma (Plasmapheresis)
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Platelets (Plateletpheresis)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Leukocytes (Leukapheresis or Leukopheresis)
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Lymphocytes (Lymphopheresis or Lymphapheresis)
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 RBC's (Erythropheresis)
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Product

• 7.1 Devices
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Disposables and Reagents
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Software
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Technology

• 8.1 Centrifugation
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Membrane Separation
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Selective Adsorption
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Procedure

• 9.1 Donor/Automated Apheresis
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Therapeutic Apheresis
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Application

• 10.1 Renal Disorders
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Hematological Disorders
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Neurological Disorders
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Autoimmune Disorders
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Others
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast

11 Market Breakup by End User

• 11.1 Blood Centers
  • 11.1.1 Market Trends
  • 11.1.2 Market Forecast
• 11.2 Hospitals
  • 11.2.1 Market Trends
  • 11.2.2 Market Forecast
• 11.3 Others
  • 11.3.1 Market Trends
  • 11.3.2 Market Forecast

12 Market Breakup by Region

• 12.1 North America
  • 12.1.1 United States
    • 12.1.1.1 Market Trends
    • 12.1.1.2 Market Forecast
  • 12.1.2 Canada
    • 12.1.2.1 Market Trends
    • 12.1.2.2 Market Forecast
• 12.2 Asia-Pacific
  • 12.2.1 China
    • 12.2.1.1 Market Trends
    • 12.2.1.2 Market Forecast
  • 12.2.2 Japan
    • 12.2.2.1 Market Trends
    • 12.2.2.2 Market Forecast
  • 12.2.3 India
    • 12.2.3.1 Market Trends
    • 12.2.3.2 Market Forecast
  • 12.2.4 South Korea
    • 12.2.4.1 Market Trends
    • 12.2.4.2 Market Forecast
  • 12.2.5 Australia
    • 12.2.5.1 Market Trends
    • 12.2.5.2 Market Forecast
  • 12.2.6 Indonesia
    • 12.2.6.1 Market Trends
    • 12.2.6.2 Market Forecast
  • 12.2.7 Others
    • 12.2.7.1 Market Trends
    • 12.2.7.2 Market Forecast
• 12.3 Europe
  • 12.3.1 Germany
    • 12.3.1.1 Market Trends
    • 12.3.1.2 Market Forecast
  • 12.3.2 France
    • 12.3.2.1 Market Trends
    • 12.3.2.2 Market Forecast
  • 12.3.3 United Kingdom
    • 12.3.3.1 Market Trends
    • 12.3.3.2 Market Forecast
  • 12.3.4 Italy
    • 12.3.4.1 Market Trends
    • 12.3.4.2 Market Forecast
  • 12.3.5 Spain
    • 12.3.5.1 Market Trends
    • 12.3.5.2 Market Forecast
  • 12.3.6 Russia
    • 12.3.6.1 Market Trends
    • 12.3.6.2 Market Forecast
  • 12.3.7 Others
    • 12.3.7.1 Market Trends
    • 12.3.7.2 Market Forecast
• 12.4 Latin America
  • 12.4.1 Brazil
    • 12.4.1.1 Market Trends
    • 12.4.1.2 Market Forecast
  • 12.4.2 Mexico
    • 12.4.2.1 Market Trends
    • 12.4.2.2 Market Forecast
  • 12.4.3 Others
    • 12.4.3.1 Market Trends
    • 12.4.3.2 Market Forecast
• 12.5 Middle East and Africa
  • 12.5.1 Market Trends
  • 12.5.2 Market Breakup by Country
  • 12.5.3 Market Forecast

13 SWOT Analysis

• 13.1 Overview
• 13.2 Strengths
• 13.3 Weaknesses
• 13.4 Opportunities
• 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

• 15.1 Overview
• 15.2 Bargaining Power of Buyers
• 15.3 Bargaining Power of Suppliers
• 15.4 Degree of Competition
• 15.5 Threat of New Entrants
• 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

• 17.1 Market Structure
• 17.2 Key Players
• 17.3 Profiles of Key Players
  • 17.3.1 Asahi Kasei Medical Co. Ltd. (Asahi Kasei Corporation)
    • 17.3.1.1 Company Overview
    • 17.3.1.2 Product Portfolio
  • 17.3.2 B. Braun SE
    • 17.3.2.1 Company Overview
    • 17.3.2.2 Product Portfolio
    • 17.3.2.3 SWOT Analysis
  • 17.3.3 Charles River Laboratories International Inc.
    • 17.3.3.1 Company Overview
    • 17.3.3.2 Product Portfolio
    • 17.3.3.3 Financials
    • 17.3.3.4 SWOT Analysis
  • 17.3.4 Fresenius Medical Care AG & Co. KGaA
    • 17.3.4.1 Company Overview
    • 17.3.4.2 Product Portfolio
    • 17.3.4.3 Financials
    • 17.3.4.4 SWOT Analysis
  • 17.3.5 Haemonetics Corporation
    • 17.3.5.1 Company Overview
    • 17.3.5.2 Product Portfolio
    • 17.3.5.3 Financials
    • 17.3.5.4 SWOT Analysis
  • 17.3.6 Haier Biomedical
    • 17.3.6.1 Company Overview
    • 17.3.6.2 Product Portfolio
  • 17.3.7 Kaneka Corporation
    • 17.3.7.1 Company Overview
    • 17.3.7.2 Product Portfolio
    • 17.3.7.3 Financials
    • 17.3.7.4 SWOT Analysis
  • 17.3.8 Medica S.p.a.
    • 17.3.8.1 Company Overview
    • 17.3.8.2 Product Portfolio
    • 17.3.8.3 Financials
  • 17.3.9 Miltenyi Biotec
    • 17.3.9.1 Company Overview
    • 17.3.9.2 Product Portfolio
  • 17.3.10 Nikkiso Co. Ltd.
    • 17.3.10.1 Company Overview
    • 17.3.10.2 Product Portfolio
    • 17.3.10.3 Financials
    • 17.3.10.4 SWOT Analysis
  • 17.3.11 Sb-Kawasumi Laboratories Inc. (Sumitomo Bakelite Company Limited)
    • 17.3.11.1 Company Overview
    • 17.3.11.2 Product Portfolio
  • 17.3.12 Terumo Bct Inc. (Terumo Corporation)
    • 17.3.12.1 Company Overview
    • 17.3.12.2 Product Portfolio